{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Galocitabine",
  "nciThesaurus": {
    "casRegistry": "124012-42-6",
    "chebiId": "",
    "chemicalFormula": "C19H22FN3O8",
    "definition": "An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5'-deoxy-5-fluorocytidine, 5'-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.",
    "fdaUniiCode": "X9788XI79O",
    "identifier": "C73254",
    "preferredName": "Galocitabine",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1557"
    ],
    "synonyms": [
      "GALOCITABINE",
      "Galocitabine",
      "Ro 09-1390"
    ]
  }
}